Dysphagia as a risk factor for mortality in Niemann-Pick disease type C: systematic literature review and evidence from studies with miglustat by Mark Walterfang et al.
Walterfang et al. Orphanet Journal of Rare Diseases 2012, 7:76
http://www.ojrd.com/content/7/1/76RESEARCH Open AccessDysphagia as a risk factor for mortality in
Niemann-Pick disease type C: systematic literature
review and evidence from studies with miglustat
Mark Walterfang1*, Yin-Hsiu Chien2, Jackie Imrie3, Derren Rushton4, Danielle Schubiger1 and Marc C Patterson5Abstract
Niemann-Pick disease type C (NP-C) is a rare neurovisceral disease characterised by progressive neurological
deterioration and premature death, and has an estimated birth incidence of 1:120,000. Mutations in the NPC1 gene
(in 95% of cases) and the NPC2 gene (in approximately 4% of cases) give rise to impaired intracellular lipid
metabolism in a number of tissues, including the brain. Typical neurological manifestations include vertical
supranuclear gaze palsy, saccadic eye movement abnormalities, cerebellar ataxia, dystonia, dysmetria, dysphagia
and dysarthria. Oropharyngeal dysphagia can be particularly problematic as it can often lead to food or fluid
aspiration and subsequent pneumonia. Epidemiological data suggest that bronchopneumonia subsequent to food
or fluid aspiration is a major cause of mortality in NP-C and other neurodegenerative disorders. These findings
indicate that a therapy capable of improving or stabilising swallowing function might reduce the risk of aspiration
pneumonia, and could have a positive impact on patient survival. Miglustat, currently the only approved
disease-specific therapy for NP-C in children and adults, has been shown to stabilise key neurological manifestations
in NP-C, including dysphagia. In this article we present findings from a systematic literature review of published
data on bronchopneumonia/aspiration pneumonia as a cause of death, and on the occurrence of dysphagia in
NP-C and other neurodegenerative diseases. We then examine the potential links between dysphagia, aspiration,
pneumonia and mortality with a view to assessing the possible effect of miglustat on patient lifespan.
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Niemann-Pick disease type C (NP-C) is a rare neurovisc-
eral disease characterised by progressive neurological de-
terioration and premature death, and has an estimated
birth incidence of 1:120,000 [1,2]. It is caused by the
autosomal recessive inheritance of mutations in either of
the two genes, NPC1 (in approximately 95% of cases) or
NPC2 (in approximately 4% of cases) [3-5]. Mutations in
either of these genes result in impaired metabolism of
endocytosed cholesterol and intracellular accumulation
of a number of lipid moieties in various tissues, particu-
larly in the brain [1,6].
Patients with NP-C usually present with one or more
neurological signs during childhood [1], although an* Correspondence: mark.walterfang@mh.org.au
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distribution, and reproduction in any mediumincreasing number of patients with adult onset of
neurological manifestations are being diagnosed based
on late-onset neurological signs and psychiatric mani-
festations [7-9]. The age at onset of neurological mani-
festations has a major influence on the rate of disease
progression and prognosis. In general, patients with
neurological onset early in life deteriorate faster and
have a shorter life expectancy than those with adult
onset [1,10-14].
The clinical presentation of NP-C is extremely het-
erogeneous. Systemic symptoms such as neonatal jaun-
dice and hepatosplenomegaly usually occur early in the
course of the disease [1,15]. Typical neurological mani-
festations include vertical supranuclear gaze palsy
(VSGP), saccadic eye movement (SEM) abnormalities,
cerebellar ataxia, dystonia, dysmetria, dysarthria and
dysphagia [1]. These neurological signs arise at different
ages, but invariably progress over time [10,16].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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in the disease course, ranging in severity from occasional
swallowing difficulties to loss of swallowing function ne-
cessitating placement of a nasogastric tube or gastrostomy
feeding [10]. Dysphagia of neurological origin arises pri-
marily from impairment in the oral and pharyngeal phases
as opposed to the later oesophageal phases of swallowing,
and as such is defined as oropharyngeal dysphagia [17].
Oropharyngeal dysphagia disrupts feeding but, more sig-
nificantly, it increases the risk of aspiration. In NP-C, it is
contributed to by bulbar motor dysfunction, dystonia, and
reduced sensation. Patients with more severe neurological
involvement generally have more severe dysphagia, and
worsening neurological involvement correlates with a
higher risk of aspirating food or fluid [18]. It is therefore
recommended that patients with impaired swallowing
function be closely monitored to avoid serious lung infec-
tions secondary to aspiration [15] and to ensure adequate
nutrition.
Data from epidemiological studies suggest that bron-
chopneumonia subsequent to food or fluid aspiration is
a major cause of mortality in NP-C and other neurode-
generative disorders. While precise causes of death are
not consistently reported in NP-C, two studies have
identified bronchopneumonia as the leading cause of
death in two separate NP-C patient cohorts, accounting
for approximately two-thirds of patients [19,20]. Marik
et al. recognised aspiration pneumonia as the leading
cause of death among a range of neurodegenerative dis-
orders [21]. Among factors known to contribute to the
development of aspiration pneumonia (e.,g., poor oral
hygiene, sleep disorders, emesis), dysphagia is considered
to contribute by far the greatest risk [22].
Substrate reduction therapy with miglustat (Zavesca®;
Actelion Pharmaceuticals) was first approved for treat-
ment of progressive neurological deterioration in children
and adults with NP-C in Europe in 2009, and has since
been approved in a number of other countries [23]. The
primary therapeutic mode of action of miglustat in NP-C
is thought to be the reduction of glucosylceramide-based
glycosphingolipid synthesis in the CNS, through the re-
versible inhibition of glucosylceramide synthase [15,24]. In
clinical studies miglustat therapy stabilised key neuro-
logical manifestations of the disease in adults and children
[25-27]. While experience with the use of miglustat in
clinical practice settings is increasing [11,18,28-31], pub-
lished data on long-term clinical outcomes in NP-C
patients receiving miglustat remain relatively scarce, owing
to the rarity of the disease.
The progressive neurodegenerative nature of NP-C and
its typically delayed diagnosis means that disease stabilisa-
tion, or a reduced rate of disease progression, are the best
attainable goals for long-term disease-specific therapy,
given that most patients have a substantial burden ofdisease by the time of diagnosis [15]. Published data sug-
gest that therapies capable of stabilising/improving swal-
lowing function can reduce the risk of aspiration
pneumonia and, potentially, reduce mortality risk [32,33].
In this article we review published information on the
most common reported causes of death in NP-C, and
evaluate disease factors that might contribute to an
increased risk of mortality. We then examine the impact
of miglustat on these disease factors to gain insight into
the potential effects of this drug on patient lifespan.
Systematic review methodology
Epidemiological research
A series of systematic epidemiological literature reviews
was conducted using the Embase online database in March
2011, to investigate several disease-related factors. Owing
to the rarity of the disease and to limited long-term out-
come reporting in NP-C (such as precise causes of death),
literature reviews examining disease factors specific to NP-
C were conducted in parallel with searches on a range of
other neurodegenerative diseases. We compared outcomes
data in NP-C with those from disorders with similar motor
manifestations (particularly dysphagia), and similar neuro-
degenerative courses [34,35]. Data from patients with acute
stroke were also evaluated because of the frequency of dys-
phagia following stroke [36]. Searches were performed to
investigate the following disease-related factors:
1. Causes of death in NP-C (key terms: NP-C,
mortality, cause of death)
2. Causes of death in progressive neurodegenerative
disease in general (key terms: mortality,
neurodegenerative disease*)
3. The prevalence of dysphagia in neurodegenerative
diseases including NP-C (key terms: swallowing,
dysphagia, neurodegenerative disease*, NP-C)
4. The association between dysphagia and aspiration
pneumonia (key terms: swallowing, dysphagia,
aspiration pneumonia, neurodegenerative disease*,
NP-C, stroke, traumatic brain injury)
5. The association between aspiration pneumonia and
mortality (key terms: death, cause of death, mortality,
aspiration pneumonia, neurodegenerative disease*,
NP-C, stroke, traumatic brain injury).
*Neurodegenerative diseases included some or all of:
Huntington's chorea, Parkinson’s disease [PD],
amyotrophic lateral sclerosis [ALS], multiple sclerosis
[MS], Alzheimer’s disease [AD], frontotemporal
dementia [FTD], Wilson’s disease, olivopontocerebellar
atrophy [OPCA], progressive supranuclear palsy [PSP],
neuroferritinopathy, motor neurone disease (MND),
neuromuscular disease and epilepsy.
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set of inclusion and exclusion criteria. Only original re-
search reports containing numerical data from clinical
assessments were included. Non-English articles were
excluded, as were reports based on preclinical data or
any duplicate reports of previously published data sets.
Research on the effects of miglustat on dysphagia and
outcomes in NP-C
Because NP-C is rare, we conducted broad literature
searches to capture any randomised controlled trials
comparing miglustat with standard (symptomatic) med-
ical management, as well as evidence from non-
randomised studies providing any additional data on
miglustat treatment in patients with NP-C.
Initial searches of Medline, Embase, the Cochrane
Central Register of Controlled Trials, the National Insti-
tutes of Health (NIH) clinical trials database (Clinical-
trials.gov) and the Australian Clinical Trials Registry
(Anzctr.org.au) were conducted in January 2010. A fur-
ther search was then repeated in March 2011 to identify
any updated published information. In addition, manual
searches were conducted using reference lists from all
relevant articles identified in the automated database
searches.
Literature review findings
Causes of death in NP-C
Out of 741 potentially relevant articles, seven were iden-
tified that specifically discussed cause(s) of death in
patients with NP-C [8,19,20,37-40]. Additional studies
were identified during the literature search, but no data
on causes of death were reported. See Additional file 1:
Table S1, for a full listing of literature search findings.
Overall, the identified studies included data from 82
patients with NP-C. While there was no specific refer-
ence to ‘aspiration pneumonia’ in the identified publica-
tions, the most frequent reported cause of death was
bronchopneumonia, based mainly on a retrospective
case study analysis in 43 UK patients [20] and a chart re-
view of 20 patients in Nova Scotia [19]. While no actual
numbers of deaths related to specific causes were
reported in the UK-based study, the major cause of
death was cited as bronchopulmonary failure with sec-
ondary infection [20]. In the Nova Scotia cohort, swal-
lowing difficulties were reported in 100% of patients,
and drooling in 95%; pneumonia was cited as the cause
of death in 12/20 (60%) patients.
In the wider community, aspiration pneumonia occurs
more frequently among individuals who are at risk of as-
piration than is reported; in many cases, it goes unrecog-
nised and is not recorded [22]. In the following
discussions regarding these and other data, it is import-
ant to consider a number of factors that contribute tothe under-reporting and/or under-recognition of the role
of aspiration pneumonia as a cause of death.
Disease coding systems can complicate the accurate
recording of precise causes of death in patients with
neurodegenerative diseases. Some coding systems re-
strict physicians to recording progression of the under-
lying (primary) disease on death certificates [41,42].
Some physicians also prefer to record a cause of death
as ‘pneumonia’ rather than ‘aspiration pneumonia’ [34].
In a large-scale study of dementia patients in England
and Wales from 1979 to 2004 [41], only half of deaths
that were attributed to ‘AD’ according to the ICD-10
classification would have been coded as such based on
ICD-9 criteria, which allowed the specification of bron-
chopneumonia and dementia. Similar results were
reported for PD patients [41].
There is currently a lack of specific or sensitive mar-
kers for aspiration, which limits the ability to discern as-
piration pneumonia from other forms of pneumonia and
results in deaths related to aspiration being recorded
under the term ‘pneumonia’ [21,43,44]. Aspiration is
considered the predominant mode of infection in noso-
comial pneumonia, mostly among the elderly [34]. How-
ever, aspiration events are rarely witnessed in patients
with aspiration pneumonia, where the clinical presenta-
tion typically matches that of community-acquired
pneumonia [21]. This is particularly relevant in patients
with ‘silent aspiration’, where aspiration occurs without
obvious clinical signs of swallowing difficulty [45].
Because of the limited number of precise data on
death in NP-C, it may be instructive to refer to data
from other, more frequent neurodegenerative diseases
that bear similarities to NP-C at the cellular and pheno-
typic level. For instance, there are a number of common
aetiological factors between Huntington's chorea and
NP-C at the level of membrane trafficking [46], and
patients with these two conditions share certain symp-
tomatologic similarities such as dystonia, motoric diffi-
culties that impair manual and oropharyngeal co-
ordination, and impairments to memory and executive
functioning that regulate feeding behaviour and the use/
retention of safe swallowing strategies. Similarly, AD
and NP-C share certain neurodegenerative pathways
and neuropathological signs [47,48].Causes of death in other neurodegenerative diseases
Data on causes of death in a variety of neurological dis-
eases including Huntington's chorea, amyotrophic lateral
sclerosis (ALS), Alzheimer’s disease (AD), frontotemporal
dementia (FTD), multiple sclerosis (MS), olivopontocere-
bellar atrophy (OPCA), Parkinson’s disease (PD), pro-
gressive supranuclear palsy (PSP) and Wilson’s disease
are listed in Additional file 2: Table S2.
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1,180 potentially relevant articles. Across all the diseases
studied, 20% of patients were classified as having died
due to ‘aspiration pneumonia’. Among patients with
Huntington's chorea, which probably most resembles
NP-C in terms of the profile of motor deficits seen, data
from the automated literature search indicated that the
overall proportion of deaths due to ‘aspiration pneumo-
nia’ or ‘pneumonia’ was 37.5% (see Additional file 1:
Tables S1, Additional file 2: Table S2, Additional file 3:
Table S3, Additional file 4: Table S4 and Additional file
5: Table S5). A further two studies were identified during
manual searching. In one study, ‘pneumonia’ was the
reported cause of death in 55% of patients, among whom
89% died due to ‘aspiration pneumonia’ [44]. In the
other study, 42% of deaths were recorded as being due
to ‘pneumonia’ [49]. Surprisingly, ‘aspiration pneumonia’
or ‘pneumonia’ were only recorded as causes of death
among 11% of ALS patients, despite that fact that most
(if not all) ALS patients in the later stages of the disease
show some degree of dysphagia [34].
In non-quantitative articles that were excluded from
the numerical analysis, aspiration pneumonia was stated
as a major cause of death in patients with neurodegen-
erative disorders, particularly in those with dysphagia
due to neurological deterioration [21,22,35]. Precise
causes of death were difficult to quantify due to incon-
sistent reporting, even in studies of more commonFigure 1 Prevalence of dysphagia in Niemann-Pick disease type C
data were available from only one study. ALS, amyotrophic lateral sclerosis;
supranuclear palsy.dementias (where ‘aspiration pneumonia’/’pneumonia’
caused 45% of deaths [50]) and PD (where aspiration
pneumonia caused up to 48% of deaths).
Dysphagia in NP-C and other neurodegenerative diseases
Among 821 potentially relevant articles identified in
the search designed to quantify the prevalence of
dysphagia in NP-C and other neurodegenerative
diseases, data from 52 studies were included for ana-
lysis (see Additional file 3: Table S3 for full data
listing). Overall, 4,065 from a total of 14,664 patients
(28%) had dysphagia. Figure 1 summarises the preva-
lence of dysphagia in each condition for which quan-
titative data were available.
The estimated incidence of dysphagia in a large study
including PD patients was low at only 8% [51], bringing
the unweighted average prevalence for PD down to 25%.
However, this study relied on ICD-9 codes for dysphagia.
The authors acknowledge that this figure is therefore
likely an underestimate. When the results from this
study are disregarded, the rate among PD patients
becomes 43%, which is closer to other reported findings
[52]. Further, the overall incidence for dysphagia
among all patients with neurodegenerative diseases
becomes 35%.
The incidence of dysphagia reported among ALS
patients was surprisingly low (24%). However, the ALS
data were strongly influenced by one large study in(NP-C) and other neurodegenerative diseases. *Conditions where
MS, multiple sclerosis, PD, Parkinson’s disease; PSP, progressive
Table 1 Relative risk of aspiration pneumonia in patients
with neurodegenerative disease or stroke and dysphagia
Source, author (year) Patient type Relative risk*
(95% CI)
Ahn et al. (2010) [54] Stroke 106 (6, 1729)
Alshekhlee et al. (2010) [55] Stroke 30 (4, 218)
Altman et al. (2010) [56] Dysphagia patients 13 (12, 13)
Aviv et al. (1997) [57] Stroke 13 (1, 216)
Chua and Kong (1996) [58] Stroke 4.6 (1.0, 20.5)
Daniels et al. (1998) [36] Stroke 1.6 (0.1, 38.0)
James (1998) [59] Stroke 4.1 (1.5, 11.4)
Meng et al. (2000) [60] Stroke 2.4 (0.1, 40.1)
Perry and McLaren (2000) [61] Stroke 21.0 (2.8, 155.9)
Schurr et al. (1999) [62] Traumatic brain injury 2.9 (0.1, 67.3)
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ferent ages at onset, and therefore likely comprised a
high proportion of patients with early-to mid-stage dis-
ease [53]. Dysphagia was reported in 30–50% of patients
among other ALS studies, and has been reported in
most if not all late-stage ALS patients [34].
Among all neurodegenerative diseases PSP appeared
to be associated with the greatest prevalence of dyspha-
gia (85%), although these data were based on only one
identified study with evaluable data. Patients with NP-C
showed the second-highest prevalence (55%), which is
substantially greater than the overall average prevalence
among neurodegenerative disease patients. Further, this
figure is likely an underestimate, as most patients
included in NP-C studies were in the early stages of dis-
ease and were being treated with miglustat.Spencer et al. (2009) [63] Stroke 11.0 (1.0, 178.3)
Sung et al. (2010) [64] Parkinson’s disease 126 (8, 2065)
*Relative risk calculated using Mantel-Haenszel fixed effects method.
Association between dysphagia and aspiration
pneumonia
Twelve out of 364 potentially relevant articles reported
data on the association between dysphagia and aspir-
ation pneumonia in patients with neurodegenerative
disease, stroke or traumatic brain injury (see Additional file
4 for full data listing). Based on relative risk analyses, these
published data consistently indicated an increased risk of
aspiration pneumonia where dysphagia was present
(Table 1). Relative risk values ranged from 1.6 (95% CI 0.1,
38.0) to 126 (95% CI 8, 2065).
Data from this literature search were combined for
meta-analysis (Figure 2). After exclusion of one very
large study [56], which included data from 77,540,204
general hospital patients resulting in unacceptably high
weighting of the overall sample (accounting for 99.8% of
all included patients), odds ratios indicated a highly sig-
nificantly increased risk of aspiration pneumonia among
patients with dysphagia. The overall odds ratio for devel-
oping pneumonia was 16.85 (95% CI 9.21, 30.83), with
values ranging from 1.7 (95% CI 0.1, 42.4) to 174 (95%
CI 10, 2,952). Analysis including data from the large
general hospital population study confirmed this finding
(odds ratio, 14.1 (95% CI 13.9, 14.3))Association between aspiration pneumonia and mortality
Five of 243 potentially relevant articles were identified
that reported data on both aspiration pneumonia and
mortality outcomes in patients with PD, stroke or epi-
lepsy (see Additional file 5: Table S5 for full data listing).
One extra article was identified in an additional hand
search of the literature that contained data from a mixed
population of patients with PD, MND, AD or Hunting-
ton's chorea [33]. No published articles were identified
that reported data on both aspiration pneumonia and
mortality in patients with NP-C.The relative risk (95% CI) of mortality among patients
with aspiration pneumonia in the identified studies ran-
ged from 1.51 (1.35,1.69) to 3.42 (0.82, 14.35) (Table 2).
When data were combined in a meta-analysis to evaluate
the relationship between these two outcomes, patients
experiencing aspiration pneumonia were seen to have an
increased risk of mortality (Figure 3). The overall odds
ratio for mortality was 3.23 (95% CI 2.46, 4.25).
Epidemiological research: overall findings
The quantitative analysis of causes of death in NP-C
patients is currently limited by the scarcity of relevant
published studies, with few reports containing mortality
data. There was limited but consistent reporting of
bronchopneumonia as the most common cause of death
in NP-C, accounting for over 60% of patients [19,20].
Supplemental analysis of data in other neurodegenera-
tive diseases that feature dysphagia showed ‘aspiration
pneumonia’ or ‘pneumonia’ reported as a cause of death
in over 20% of patients. However, this is considered to
be vastly underestimated due to a number of factors that
contribute to under-reporting of aspiration pneumonia
as cause of death.
The analysis of published data in NP-C and a range of
other neurodegenerative diseases showed that dysphagia
is a frequent symptom, particularly in NP-C and PSP.
Further, relative risk data and meta-analyses provide
clear evidence that patients with dysphagia are at an
increased risk of developing aspiration pneumonia, and
that there is a strong link between the occurrence of as-
piration pneumonia and mortality risk. With these links
now established, the following sections specifically
examine the effects of miglustat therapy on dysphagia


























































































AP in pts with Dys AP in pts without Dys Odds Ratio Odds Ratio
M-H, Fixed, 95% CI
0.01        0.1           1           10          100
Favours experimental    Favours control
Total events                           127
Heterogeneity. Chi2 = 15.37, df = 10 (P = 0.12), 12 = 35%
Test for overall effect Z = 9.16 (P <0.00001)
Figure 2 Odds ratios for association between dysphagia and aspiration pneumonia in patients with neurodegenerative diseases and
stroke. M-H, Mantel-Haenszel fixed effects method. Note: Altman et al. [56] paper excluded.
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miglustat on dysphagia in NP-C
All published clinical studies providing data on swallow-
ing function in miglustat-treated patients are sum-
marised in Table 3.Swallowing assessments based on clinical judgment
Swallowing function data were available from a 12-
month randomised, controlled trial that assessed the ef-
ficacy, safety and tolerability of miglustat 200 mg t.i.d. in
juvenile and adult patients aged ≥12 years (n = 29), com-
pared with standard care [25]. Findings were also
reported from a parallel non-controlled sub-study of this
trial, which assessed miglustat in children aged 4–
11 years (n = 12) [25].
Long-term data from patients continuing miglustat
therapy during 12-month open-label extensions of the
main juvenile/adult study (n = 21) and the paediatric
sub-study (n = 10) have since been published [26,27]. InTable 2 Relative risk of mortality in patients with
neurodegenerative disease or stroke and aspiration
pneumonia
Source, author (year) Patient type Relative risk*
(95% CI)
Ali et al. (2008) [65] Stroke 3.42 (0.82, 14.35)
Amare and Amanuel (2008) [66] Epilepsy 1.90 (0.88, 4.10)
Aslanyan et al. (2004) [67] Stroke 2.58 (1.82, 3.66)
Fernandez and Lapane (2002) [68] Parkinson’s
disease
1.51 (1.35,1.69)
Low et al. (2001) [33] Dysphagia
patients
2.58 (1.77,3.78)
Marwat et al. (2010) [69] Stroke 3.10 (0.74, 12.93)
*Relative risk calculated using Mantel-Haenszel fixed effects method.each of these reports dysphagia was assessed based on
standardised clinical assessments of the patients’ ability
to swallow different foods (e.g. water, puree, soft pasta/
noodles, a cookie), graded using a five-point categorical
scale: ‘no problems swallowing’, ‘mild problems’, ‘moder-
ate problems’, ‘severe problems’, or ‘could not swallow
at all’.
Retrospective data on swallowing function were
reported in an international, multicentre, observational
cohort study that evaluated neurological disease pro-
gression in patients treated with miglustat in clinical
practice settings (n = 66) [70]. Swallowing function was
evaluated based on patients’ scores on the dysphagia
subscale of a modified, disease-specific disability scale
[12]. Using this subscale the degree of dysphagia be-
fore miglustat therapy, at treatment initiation, and after
therapy was rated as ‘normal’ (score = 0), ‘occasional
dysphagia’ (score = 0.33), ‘daily dysphagia’ (score = 0.66),
or ‘nasogastric tube or gastric button feeding’ (score =
1) [70]. Data then underwent categorical analysis for
‘improvement’, ‘stabilisation’ or ‘worsening’ of swallow-
ing function.
Swallowing assessments based on instrumental methods
Findings from instrumental, quantitative assessments of
swallowing have been reported from two studies [18,29].
Both reports were based on longitudinal case analyses
incorporating videofluoroscopic studies (VFSS), which
are considered the gold standard method for studying
oropharyngeal swallowing function. VFSS allow the in-
depth evaluation of all phases of the swallowing motion,
enabling clear distinctions between oral-phase and
pharyngeal phase dysfunction [71].
Fecarotta et al. reported findings from detailed serial
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M-H, Fixed, 95% CI
Deaths Related to AP Deaths Unrelated to AP Odds Ratio
Total events                           160
Heterogeneity. Chi2 = 3.36, df = 5 (P = 0.64), 12 = 0%
Test for overall effect Z = 8.42 (P < 0.00001)
Figure 3 Odds ratios for association between aspiration pneumonia and mortality outcomes. M-H, Mantel-Haenszel fixed effects method.
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patient with severe early-infantile onset NPC2 [18].
These patients received miglustat therapy, dosed accord-
ing to BSA for between 3 and 4 years. The severity of
dysphagia was evaluated at 2–6 monthly intervals based
on an adapted version of the 6-point Dysphagia Severity
Score (DSS) [71], which ranges from normal swallowing
(score = 0) to severe dysphagia with potential for aspir-
ation (score = 5). A 7-point Penetration-Aspiration Score
(PAS) was also applied at each VFSS assessment to
quantify penetration/aspiration in the airways according
to published methods [71]; again, higher scores on this
scale indicated more severe impairment. VFSS were also
conducted in parallel with NP-C disability scale assess-
ments to assess correlations between swallowing func-
tion, overall neurological deterioration (based on
composite disability scores [70]) and the dysphagia sub-
scale scores.
Chien et al. reported data from two young symptom-
atic male patients with juvenile-onset NP-C who com-
pleted 1 year of miglustat therapy, dosed according to
body surface area. One patient had severely impaired
swallowing function, and the second displayed normal
swallowing but impaired language and speaking ability
prior to miglustat therapy [29]. Videotapes of VFSS of
liquid barium swallowing were analysed by a single radi-
ologist based on the Han functional dysphagia scale [72].
Scores were assigned to 11 variables that covered the
‘entire swallowing cycle’ or ‘all aspects of the oropharyn-
geal swallow’. Individual scores assessing each of these
variables were summated to provide a total functional
dysphagia score ranging from 0 (no impairment) to 100
(severe impairment).
Results from studies of the effects of miglustat on
dysphagia in NP-C
Categorical data findings
Based on clinical judgment, miglustat was reported to
stabilise or improve swallowing function in a substantial
proportion of patients with NP-C.In the randomised controlled trial, improvements were
seen in the ability to swallow water for six patients
(30%), puree for three patients (15%), soft lumps for
three patients (15%), and a third of a cookie for seven
patients (35%) after 12 months of therapy [25]. The pro-
portions of miglustat-treated juvenile/adult patients
reporting no difficulty swallowing water, puree and one-
third of a cookie after 12 months of miglustat therapy
increased from baseline by 10–25% (Figure 4). In con-
trast, the proportions of juvenile/adult patients on stand-
ard care who showed no difficulty swallowing were
either equal to or lower than baseline at 12 months.
In the non-controlled extension study [27], swallowing
was improved or stable (versus baseline) in 86% of all ju-
venile/adult patients who completed 12 months of
miglustat therapy (n = 21), and in 79–93% of those com-
pleting 24 months on miglustat (n = 15), depending on
the substance assessed.
Swallowing difficulties were less common in the paedi-
atric sub-study population (recorded in only 33% of
patients at baseline) [25]. Over 80% of children swal-
lowed all four test substances easily before treatment
was started. It was therefore anticipated that improve-
ments in swallowing were not likely. A worsening in the
ability to swallow water, puree, soft lumps and one-third
of a cookie was noted after 12 months of therapy in
three patients (27%), two patients (18%), one patient
(9%) and two patients (18%), respectively. However,
among 10 paediatric patients who participated in and
completed extension treatment, only one showed deteri-
oration in the ability to swallow one-third of a cookie
after 24 months of therapy. All other patients showed no
change in swallowing function from baseline.
Dysphagia assessments in NP-C patients included in
the retrospective observational NP-C cohort indicated
similar findings among patients treated outside the con-
text of clinical trials [70]. The retrospective cohort com-
prised 66 patients with a mean (SD) age at diagnosis of
9.7 (7.6) years; the mean (SD) age at treatment start was
12.8 (9.5) years. On average, patients had been under
Table 3 Summary of randomised and non-randomised studies with information on the effects of miglustat on
dysphagia
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http://www.ojrd.com/content/7/1/76observation for a mean (SD) period of 3.1 (3.4) years be-
tween diagnosis and initiation of miglustat therapy.
In line with other data on the natural history of NP-C
[10,16], composite NP-C disability scale scores indicated
marked neurological deterioration before the initiation
of miglustat therapy [70]. On the dysphagia subscale,
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Figure 4 Effect of miglustat versus standard care on swallowing abilit
controlled trial. Reproduced with permission from [25].or occasional dysphagia at diagnosis, this had dropped
to 66% by the end of the pre-treatment observation
period. In contrast, the proportion of patients with nor-
mal swallowing or occasional dysphagia after a median
(range) of 1.5 (0.1–4.5) years’ miglustat treatment was
almost identical to that at the start of therapy (67%).
Overall, 51/63 (81.0%) patients showed a stable/85%
95%
88% 88%
1 teaspoon of purée





One-third of a cookie
Standard care, baseline Standard care, last visit
y in adolescent/adult patients over 12 months in a randomised,
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treatment.
Instrumental assessments of swallowing
Findings from direct instrumental assessments of the
effects of miglustat on swallowing function, based on
VFSS [18,29], support categorical data based on clinical
observation of dysphagia [25–27,70].
In the Italian case series, where serial VFSS were con-
ducted to quantify changes in swallowing function dur-
ing 36–48 months of miglustat therapy, all three
patients with dysphagia at treatment start showed early
improvements in swallowing ability (DSS scores), and
one patient who did not exhibit dysphagia before
therapy showed stable swallowing function throughout
treatment [18]. Improvements in swallowing ability, par-
ticularly in terms of pharyngeal phase function, occurred
in parallel with improvements or stabilisation of overall
neurological manifestations assessed by composite NP-C
disability scores. These apparent long-term beneficial
effects of miglustat on swallowing function were asso-
ciated with sustained reductions in penetration/aspir-
ation (based on PAS scores) in all patients who showed
severe swallowing impairment and aspiration prior to
treatment.
Impairments of pharyngeal swallowing function
tended to occur later in the course of NP-C than oral-
phase impairment, and more severe pharyngeal-phase
involvement associated with penetration/aspiration of
contrast agent in the airways was present in patients
with the most severe overall neurological impairment
[18]. Further, in all patients in this case series, improve-
ments in pharyngeal swallowing function during miglu-
stat therapy were greater, and occurred earlier, than
those in the oral phase. Modest impairment in the pre-
paratory/oral phase persisted during follow up in two
patients with severe swallowing impairment (and higher
NP-C disability scale scores) at treatment start.
It can be speculated that the apparent difference in the
effects of miglustat on pharyngeal versus oral-phase
swallowing function might reflect selective therapeutic
effects of miglustat on the neurological pathways that
control them [18]. While the preparatory/oral phase is
activated by peripheral receptors as well as through
stimulation of sensory cortical neurones, the pharyngeal
and oesophageal phases are mediated by involuntary
reflexes dependent on brainstem neurones. Since greater
therapeutic effects were noted for pharyngeal phase
swallowing, it might be that miglustat affects autonomic,
brainstem-based neuronal circuits before higher, cortical
centres in NP-C. The significant effects of miglustat on
saccadic eye movements (which are also modulated by
pathways in the brainstem) during the randomised clin-
ical trial would certainly seem to support this [25].Data reported from two male Taiwanese patients sup-
port findings from the Italian cohort [29]. In the patient
with pronounced swallowing impairment, who had dis-
played neurological manifestations since 5 years of age,
VFSS identified severe oropharyngeal dysphagia and
prominent aspiration before miglustat treatment was
initiated at the age of 14 years. Distinct improvements in
swallowing function were seen after 6 months of ther-
apy, reflected by a 25% reduction in Han functional dys-
phagia scale score that was sustained through to Month
12. Similar to findings reported in the Italian case series
[18], this patient’s improved swallowing function oc-
curred simultaneously with improvements in ambulation
[29]. The second patient, who had displayed splenomeg-
aly since birth and behavioural problems (Asperger-like
syndrome) since the age of 8 years, did not display sig-
nificant swallowing impairment either before treatment
or during therapy, but did show improvements in com-
munication, social interaction and cognitive function by
Month 12 [29].Data limitations
In assessing the available published data on the effects of
miglustat on dysphagia in NP-C, a number of limitations
should be taken into account. NP-C is markedly hetero-
geneous and different patient cohorts have limited com-
parability, particularly in terms of age at neurological
disease onset [1,10]. Most published evidence related to
changes in swallowing function during miglustat therapy
stems from subjective assessments (i.e. clinical observa-
tion and disability scales) rather than direct, quantitative
swallowing studies such as those employed in the Italian
cohort and Taiwanese case reports [18,29]. Dysphagia in
NP-C often has mixed motor and sensory components,
and silent aspiration of small or trace amounts of food
or fluid is not well diagnosed without direct VFSS. Fi-
nally, the inclusion in this analysis of the retrospective
miglustat observational cohort study [70] introduces po-
tential bias, so the contribution of these data, albeit
based on an established disease-specific disability scale,
should be considered with caution.
Longitudinal analysis of survival in miglustat-
treated patients
Analysis methods
To identify the effect of miglustat on patient survival,
longitudinal statistical analyses were conducted based on
all available published data from miglustat-treated
patients and from an untreated cohort. Patient age at
onset of neurological manifestations has previously been
shown to have a strong influence on the severity, pro-
gression and prognosis of NP-C [1,10,15,70]. An analysis
of patient survival was therefore conducted based on
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onset, from the overall groups of untreated and treated
patients identified during our analyses of published data.
Patient survival was then compared between the overall
treated and untreated patient groups.
Survival analyses were based on both univariate and
multivariate methods. A univariate Kaplan-Meier ana-
lysis using the log-rank test evaluated survival over time,
and multivariate Cox proportional hazards modelling
was performed to provide estimates of overall mortality
risk per treatment group and according to patient age.
Analyses in miglustat-treated patients were based on
time from the start of therapy as ‘age at neurological dis-
ease onset’ data were not available for many patients.
However, analyses in untreated patients were based on
time from onset of neurological manifestations, as most
patients had available data [1].
Results
The untreated group comprised patients from the
French NP-C cohort [1]. This population provided longi-
tudinal data from a total of 97 patients diagnosed in
French hospitals (Table 4). Nineteen patients were
excluded from this control cohort as they died during
the first days or months of life, and would therefore not
have been eligible to receive miglustat therapy (see
Data limitations).
The treated group (N = 90) comprised patients from
the randomised controlled trial (n = 25) [25], the Italian
cohort (n = 4) [18], and the retrospective observational
cohort (n = 61) (Table 4). A number of patients were
excluded from this data set due to non-availability of
data, or to avoid overlap between different publications
based on the same patients. Seven patients from the ran-
domised trial data set were excluded. Six of these cases
did not have a time of neurological onset recorded at
baseline, disallowing their inclusion in the analysis. The
seventh patient only received miglustat for 71 days,
which made it very unlikely that a visible therapeuticTable 4 Mortality in untreated and miglustat-treated




n (N = 97) n (N = 90)
Overall 74 (76) 3 (3)
Age category*
<2 years 27 27 (100) 4 0 (0)
2–11 years 48 40 (83) 37 2 (5)
>11 years 22 7 (32) 49 1 (2)
*Age at neurological symptom onset in untreated patients, and age at
treatment start in treated patients.response could be expected. Taiwanese patients (n = 2)
[29] and patients from a Spanish clinical experience co-
hort (n = 16) [11] were excluded as they formed part of
the retrospective cohort.
Findings from Kaplan-Meier log-rank analysis in dif-
ferent age-at-onset subgroups of untreated patients
were in line with previous data on the natural history
of NP-C [10]. Untreated patients with neurological dis-
ease onset at <2 years of age showed the lowest sur-
vival rate over a 10-year period of follow up, while
patients with onset aged 11+ years had the best sur-
vival rate (Figure 5).
Analyses of survival by age at neurological onset
among miglustat-treated patients were limited by low
patient numbers and relative lack of long-term follow
up among the available published data. No Kaplan-
Meier curve was possible for treated patients with dis-
ease onset at <2 years of age as there were no deaths
in this subgroup. Likewise, no meaningful analysis was
possible for treated patients with neurological onset at
>11 years of age, as only one patient in this subgroup
died (early during miglustat therapy). Kaplan-Meier
analysis was only possible for the 2–11 year age at
onset subgroup, and showed a numerically better sur-
vival rate (2 deaths among 37 patients) during approxi-
mately 2.5 years of follow up versus the equivalent age
subgroup of untreated patients (40 deaths among
48 patients).
In the overall treated versus untreated group analysis,
a total of 74 patients died in the untreated group com-
pared with just three patients in the treated group, lead-
ing to a large numerical difference in the overall
mortality rates between the two groups; 76% versus 3%,
respectively. However, Cox proportional hazard model-
ling did not establish statistical significance for this dif-
ference after adjusting for age (p = 0.34; hazard ratio
[95% CI] for treated vs. untreated, 0.56; 0.17, 1.86), likely
due to the very low number of deaths and relatively
short follow-up time in the treated group. Kaplan-Meier
analysis with univariate log-rank testing identified a sig-
nificant difference in mortality between the treated and
untreated groups (p = 0.044) (Figure 6).
Patient age at treatment start (in treated patients) and
age at neurological symptom onset (in untreated
patients) were found to have a very significant influence
on survival. Cox proportional hazard modelling showed
that, among all patients (treated and untreated), patients
aged <2 years had a significantly higher mortality rate
(87%, p < 0.0001; hazard ratio [95% CI], 5.56 [3.08,
10.13]) compared with 49% in patients aged 2–10 years
(the reference group). Conversely, patients aged >11 years
had a significantly lower rate (11%, p = 0.0003; hazard




















Treated  (n = 90)
Untreated (n = 97)
p = 0.044 (untreated vs. 
treated; log-rank test)
0 1 2 3 4 5 6 7 8 9 10
Figure 5 Influence of age at neurological onset on patient survival in untreated NP-C patients. Kaplan-Meier log-rank analysis of mortality
by age at neurological disease onset in untreated patients.
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A number of data limitations should be acknowledged in
considering the results of these survival analyses, which
are chiefly related to the composition and nature of the
treated cohort compared with the untreated cohort. The
untreated patient data used in these statistical compari-
sons are derived solely from the French NP-C cohort,
while data from miglustat-treated patients are derived
from a multinational group of patients who were
included in a number of different studies.
There were large differences in the length of follow
up in treated patients compared with untreated


















Untreated, <2 years (n = 27) 
Untreated, 2−11 years (n = 48)
Untreated, 11+ years  (n = 22)
Figure 6 Influence of miglustat therapy on NP-C patient survival. Kap
patients and since age at neurological disease onset in untreated patients.proximately 1 month to 5 years among patients
included in the randomised controlled trial, retro-
spective cohort study and Italian cohort [25,70,73],
compared with approximately 23 years in the un-
treated cohort [1]. More specifically, while the un-
availability of data for age at onset of neurological
manifestations for many of the treated patients
necessitated a comparison of survival from treatment
start (in treated patients) with survival from neuro-
logical disease onset (in untreated patients), such a
comparison presents difficulties.
Published data indicate that substantial periods of
time (and likely, significant disease progression) may5 6 7 8 9 10
Years
lan-Meier log-rank analysis of mortality since treatment start for treated
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miglustat treatment, due either to diagnostic delay
or the date at which miglustat became available (or
both) [11,70]. Thus, some patients in the treated
group might have progressed significantly before
treatment initiation, while in some treated patients
miglustat therapy might have been initiated after a
relatively short period of time after neurological dis-
ease onset. However, given the low numbers of
patients available for this assessment, it is not pos-
sible to properly assess the influence of this
difference.
The untreated patient data constitute an un-
matched (and generally younger) control cohort
compared with the treated patients in terms of age.
The mean (SD) age at treatment start in the rando-
mised controlled trial of miglustat was 25.4 (9.8)
years in adolescent/adult patients (range 12–42 years;
n = 20) and 7.2 (2.5) years in paediatric patients
(range 4–11 years; n = 12) [25]. The mean (SD) age
at treatment start in the retrospective NP-C cohort
study was 12.8 (9.5) years (range 0.6–43 years; n =
66). The mean age at treatment start in the Italian
case series was 8.0 (4.9) years (range 0.9–12 years; n
= 4). In contrast, the patient age at neurological
symptom onset ranged between approximately
6 months and 55 years; 50% of patients were aged
<5 years at onset, and a further 25% were aged
<10 years. While both the Kaplan-Meier and Cox
proportional hazard modelling analyses of patient
survival were controlled for patient age, it cannot be
discounted that age-related disease natural history
might still have had an influence on the apparent
difference in patient survival between the treated
and non-treated groups.
It is possible that differences in regional population char-
acteristics (e.g. lifestyle, diet, symptomatic therapies) be-
tween the treated and untreated cohorts could have
contributed to, or in some other way influenced, the appar-
ent treatment difference. However, it should be remem-
bered that NP-C is pan-ethnic and occurs sporadically
across populations, regardless of race. Differences in race
per se were not expected to affect the study results.
Finally, while each of the published studies assessing
miglustat therapy that were identified in this analysis
made efforts to minimise bias, a number of sources of
potential bias were inherent following their inclusion in
the overall treated group. In particular, while there was
minimal selection bias in the randomised, controlled
trial of miglustat in NP-C, neither severely affected
patients nor symptom-free patients were included in the
study [25]. The exclusion of severely affected patients
may remove those who were unlikely to improve, result-
ing in a positive bias (i.e. inclusion of patients morelikely to improve). Conversely, non-inclusion of asymp-
tomatic patients might exclude those whose symptom
onset may be significantly delayed, thus extending the
apparent survival (negative bias).
Safety and tolerability of miglustat in NP-C
While miglustat has been shown to be generally well
tolerated in patients with NP-C, the perceived safety
and tolerability profile of any drug can affect treat-
ment compliance and can thus impact on clinical ef-
ficacy. Similar to previous observations in patients
with Gaucher disease type 1 [23,74-78], the principal
adverse events observed during clinical studies with
miglustat in patients NP-C were gastrointestinal in
nature [11,23,25-27,79].
During clinical trials and subsequent clinical experi-
ence, diarrhoea, flatulence, bloating and abdominal pain/
discomfort were the most commonly reported adverse
events associated with miglustat, particularly during the
initial weeks/months of therapy [79]. While frequently
observed, these gastrointestinal disturbances are gener-
ally mild or moderate in severity and usually resolve
spontaneously with time on continued therapy [79].
Where required, diarrhoea can effectively be controlled
using anti-propulsive medications, used according to the
respective manufacturers’ prescribing information. Diet-
ary modifications such as restriction of disaccharides or
general, controlled reductions in overall carbohydrate in-
take can improve the gastrointestinal tolerability of
miglustat, particularly if initiated before the start of ther-
apy. Such dietary modifications should be undertaken
over a course of weeks or months, with patients grad-
ually being re-introduced to a normal diet dependent on
tolerability [79,80].
Conclusions
Published data indicate that aspiration pneumonia is the
most common cause of death in neurodegenerative dis-
eases, including NP-C, and that dysphagia can reliably
be considered as a risk factor for mortality as it is a fre-
quent cause of aspiration pneumonia.
Miglustat has been shown to stabilise neurological
manifestations of NP-C. Beneficial effects of miglustat
on swallowing function have been reported in a number
of previously published studies based on clinical judg-
ment and quantitative, instrumental VFSS.
Our findings based on systematic literature analyses
and statistical survival evaluations suggest that NP-C
patients receiving miglustat therapy may have a greater
lifespan compared with untreated patients, and that this
effect is likely related to a beneficial effect of miglustat
on dysphagia. Because of the extremely variable nature of
this disease and the limited published data, further, longer-
term data are required to confirm this apparent effect.
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